← Back to Screener
Metagenomi Therapeutics, Inc. Common Stock (MGX)
Price$1.44
Favorite Metrics
Price vs S&P 500 (26W)-58.84%
Price vs S&P 500 (4W)-5.82%
Market Capitalization$54.17M
All Metrics
Book Value / Share (Quarterly)$4.22
Indicated Dividend (Annual)$0.00
Revenue Growth (3Y)13.59%
Cash Flow / Share (Quarterly)$-2.38
Price vs S&P 500 (YTD)-13.75%
Net Profit Margin (TTM)-348.54%
EPS (TTM)$-2.36
10-Day Avg Trading Volume0.17M
EPS Excl Extra (TTM)$-2.36
EPS (Annual)$-2.36
ROI (Annual)-55.40%
Net Profit Margin (5Y Avg)-1945.52%
Cash / Share (Quarterly)$4.27
Revenue Growth QoQ (YoY)-59.32%
ROA (Last FY)-39.74%
Revenue Growth TTM (YoY)-51.79%
EBITD / Share (TTM)$-2.44
ROE (5Y Avg)-37.04%
Operating Margin (TTM)-380.85%
Cash Flow / Share (Annual)$-2.38
P/B Ratio0.34x
P/B Ratio (Quarterly)0.38x
Net Income / Employee (Annual)$-1
EV / Revenue (TTM)0.49x
ROA (TTM)-33.82%
EPS Incl Extra (Annual)$-2.36
Current Ratio (Annual)7.22x
Quick Ratio (Quarterly)7.03x
3-Month Avg Trading Volume0.27M
52-Week Price Return-5.26%
Revenue / Employee (TTM)$0
P/S Ratio (Annual)2.15x
Asset Turnover (Annual)0.11x
52-Week High$3.95
Operating Margin (5Y Avg)-2168.10%
EPS Excl Extra (Annual)$-2.36
26-Week Price Return-54.86%
Quick Ratio (Annual)7.03x
13-Week Price Return-17.71%
Total Debt / Equity (Annual)0.00x
Current Ratio (Quarterly)7.22x
Enterprise Value$12.452
Asset Turnover (TTM)0.10x
Revenue / Employee (Annual)$0
Pretax Margin (Annual)-348.77%
Cash / Share (Annual)$4.27
3-Month Return Std Dev59.65%
Net Income / Employee (TTM)$-1
ROE (Last FY)-55.40%
EPS Basic Excl Extra (Annual)$-2.36
Receivables Turnover (TTM)32.28x
Total Debt / Equity (Quarterly)0.00x
EPS Incl Extra (TTM)$-2.36
Receivables Turnover (Annual)32.28x
ROI (TTM)-47.14%
P/S Ratio (TTM)2.15x
Pretax Margin (5Y Avg)-1941.11%
Revenue / Share (Annual)$0.68
Price vs S&P 500 (52W)-35.09%
Year-to-Date Return-11.11%
5-Day Price Return3.60%
EPS Normalized (Annual)$-2.36
ROA (5Y Avg)-21.62%
Net Profit Margin (Annual)-348.54%
Month-to-Date Return7.46%
EBITD / Share (Annual)$-2.44
Operating Margin (Annual)-380.85%
LT Debt / Equity (Annual)0.00x
ROI (5Y Avg)-33.06%
LT Debt / Equity (Quarterly)0.00x
EPS Basic Excl Extra (TTM)$-2.36
P/B Ratio (Annual)0.38x
Pretax Margin (TTM)-348.77%
Book Value / Share (Annual)$4.22
Price vs S&P 500 (13W)-18.40%
Beta1.72x
P/FCF (Annual)3.44x
Revenue / Share (TTM)$0.67
ROE (TTM)-47.14%
52-Week Low$1.25
Analyst Recommendations
Jan 2026
Feb 2026
Mar 2026
Apr 2026
4.00
4.00
4.00
4.00
Industry Peers — Biological Products(88)
| Symbol | P/S Ratio (TTM) | Revenue Growth TTM (YoY) | Gross Margin (TTM) | EPS Growth (5Y) | Price |
|---|---|---|---|---|---|
MGXMetagenomi Therapeutics, Inc. Common Stock | 2.15x | -51.79% | — | — | $1.44 |
AMGNAmgen Inc | 5.13x | 9.95% | 73.30% | 2.93% | $349.39 |
GILDGilead Sciences Inc | 5.84x | 2.40% | 78.83% | 133.64% | $138.55 |
ARGXargenx SE American Depositary Shares | 12.46x | 89.56% | 150.91% | — | $828.35 |
BNTXBioNTech SE American Depositary Share | 8.75x | -11.81% | 84.21% | — | $102.12 |
BIIBBiogen Inc. Common Stock | 2.60x | 2.22% | 75.69% | -18.77% | $176.02 |
MRNAModerna, Inc. Common Stock | 11.02x | -39.93% | 70.32% | — | $54.68 |
NBIXNeurocrine Biosciences Inc | 4.49x | 21.45% | 98.18% | 2.31% | $128.41 |
EXELExelixis Inc | 4.96x | 6.85% | 96.39% | 31.10% | $44.38 |
TECHBio-Techne Corp. | 7.60x | 1.64% | 66.60% | -20.58% | $57.36 |
HALOHalozyme Therapeutics, Inc. | 5.74x | 37.55% | 83.62% | 22.89% | $66.64 |
About
Metagenomi Therapeutics is a genetic medicines company developing in vivo gene editing therapies using its proprietary metagenomics-derived platform. The company's pipeline targets hemophilia A, refractory hypertension, and cardiovascular diseases. Its comprehensive editing toolbox includes programmable nucleases, base editors, and CRISPR-associated transposases, with the company also pursuing technology licensing for ex vivo cell therapy applications.